date:Oct 31, 2018
ion of continuing implementation and making meaningful progress on the Action Plans commitments in the months and years ahead.
As a first step, the FDA will adopt a comprehensive policy framework for the development and regulatory oversight of animal biotechnology products, including for intentionally genetically altered animals and the food and drug products derived from them. This modern, flexible framework will advance the agencys commitment to safety while promoting innovation in this space